The recent scientific breakthroughs in understanding the interplay between the immune system, the oral microbiota, and the SARS-CoV-2 virus have paved the way for exciting revelations in the field of probiotics. A groundbreaking study, led by Andrey Kruglov and his team, sheds light on the cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and the commensal microbiota, particularly the role of BLIS K12™ Streptococcus salivarius (S. salivarius) in enhancing protective immunity.
The Dance of Immunity and Microbiota:
The study reveals that SARS-CoV-2 vaccination triggers an early increase in S. salivarius levels in the oral cavity. This spike in BLIS K12™ is not a mere coincidence but a result of the molecular mimicry mechanism. Antibodies produced in response to the viral Spike protein also bind to BLIS K12™, thanks to molecular mimicry.
The researchers found that BLIS K12™, a member of the human microbiota, induces cross-reactive anti-Spike antibodies in mice, aiding in the clearance of the SARS-CoV-2 virus. Furthermore, specific proteins within BLIS K12™, such as RSSL-01370, show homology to the Spike receptor-binding domain.
Immunization with RSSL-01370 in mice resulted in the production of anti-Spike antibodies, emphasizing the potential of BLIS K12™ as a key player in enhancing immunity.
Read full study here: https://doi.org/10.1016/j.chom.2023.10.007
In conclusion, the symbiotic relationship between the immune system and the microbiota, particularly BLIS K12™, has far-reaching implications in the post-SARS-CoV-2 vaccination landscape. As we continue to unravel the intricate dance between antibodies, microbes, and immunity, the role of probiotics becomes increasingly significant. Our commitment to providing cutting-edge probiotic solutions remains steadfast, with BLIS K12™ at the forefront of promoting a healthier and more resilient future.
To explore more opportunities with BLIS K12™, get in touch: